Avecho Biotechnology Ltd

Avecho Biotechnology (ASX: AVE) has received a maiden payment of approximately $4.7 million (US$3m) from international generic and biosimilar medicines specialist Sandoz. The payment forms part of a recently signed licensing agreement for the commercial rights to develop Avecho’s proprietary cannabidiol (CBD) product for insomnia treatment in Australia. Avecho has granted Sandoz exclusive commercial rights […]

Avecho Biotechnology (ASX: AVE) has signed an exclusive 10-year development and licensing agreement with Swiss generic pharmaceuticals developer Sandoz Group to investigate the commercialisation of a cannabidiol (CBD) capsule for insomnia in Australia. The companies have identified a market in which nearly 9.5 million Australians experience symptoms of insomnia, with approximately 3.6 million of those […]

Long-term efforts by Avecho Biotechnology (ASX: AVE) to further the clinical and commercial potential of its TPM (tocopheryl phosphate mixture) enhanced products gained traction during the three months to end June. In May, the US Patent and Trade Marks Office allowed the company a new patent application covering an optimised manufacturing process for TPM. When […]

Pharmaceutical company Avecho Biotechnology (ASX: AVE) has passed a crucial two-year stability point milestone for its tocopheryl phosphate mixture (TPM)-enhanced cannabidiol (CBD) soft-gel capsule. Cannabinoids are susceptible to degradation from a number of external sources including oxygen, light, heat and acidity, which can often create challenges with long-term pharmaceutical stability. Specific cannabinoids (such as non-psychoactive […]